As China’s first approved CAR-T therapy, Yescarta (axicabtagene ciloleucel, axi-cel) has established itself as one of the most extensively studied CAR-T products worldwide. Supported by five-year follow-up data, breakthrough second-line treatment results, and real-world evidence from China, Yescarta is providing new hope for patients with relapsed or refractory large B-cell lymphoma (LBCL), demonstrating the potential for long-term disease control and even clinical cure.
What is Yescarta?
CAR-T cell therapy is an innovative personalized treatment that uses a patient’s own immune T cells. These cells are collected from the patient, genetically modified to recognize cancer cells, expanded in specialized laboratories, and then infused back into the patient.
The engineered CAR-T cells function like a highly trained anti-cancer task force, capable of identifying and eliminating lymphoma cells that express the CD19 target. Unlike conventional drugs, CAR-T cells can remain active in the body for extended periods, continuously monitoring and attacking cancer cells. This unique characteristic has led many experts to describe CAR-T therapy as a “living drug.”
Yescarta is a CD19-directed autologous CAR-T therapy developed specifically for large B-cell lymphoma. Since its introduction, more than 25,000 patients worldwide and over 1,400 patients in China have received treatment with Yescarta, making it one of the most widely utilized and extensively followed CAR-T therapies globally.
Strong Clinical Evidence Supports Long-Term Survival
Multi-Line Relapsed or Refractory Patients: Delivering Long-Term Survival
For patients whose disease has failed multiple previous treatments, long-term data from the landmark ZUMA-1 trial demonstrated remarkable durability.
Five-year follow-up results showed:
- 5-year overall survival (OS): 42.6%
- 5-year OS among patients achieving complete response (CR): 64.4%
Researchers also observed a clear survival plateau, suggesting that patients remaining disease-free after several years may have a substantially reduced risk of relapse. This finding supports the possibility of long-term remission and potential clinical cure for a significant proportion of patients.
Second-Line Treatment: Moving CAR-T Earlier Improves Outcomes
For patients whose disease is refractory to first-line therapy or relapses within 12 months, early intervention with CAR-T therapy has demonstrated significant advantages.
The pivotal ZUMA-7 trial compared Yescarta directly against conventional second-line treatment strategies. Results showed:
- Complete response rate: 65%
- 4-year overall survival: 54.6%
Importantly, ZUMA-7 became the first study in nearly three decades to demonstrate a significant overall survival advantage in the second-line setting for LBCL. These findings support the strategy of moving CAR-T therapy earlier in the treatment journey to maximize the opportunity for long-term survival.
High-Risk and Special Patient Populations
Yescarta has also demonstrated encouraging outcomes in several difficult-to-treat patient populations.
High-Risk Newly Diagnosed Patients
The ZUMA-12 study evaluated early CAR-T intervention in high-risk patients with inadequate responses to initial therapy.
Results included:
- Complete response rate: 86%
- 3-year overall survival: 75.1%
These findings suggest that earlier CAR-T treatment may improve outcomes for patients at particularly high risk of relapse.
Patients Ineligible for Stem Cell Transplant
Many older or medically fragile patients are unable to tolerate high-dose chemotherapy followed by autologous stem cell transplantation.
The ALYCANTE study reported:
- Complete response rate: 71%
This provides an important treatment option for patients who previously had limited alternatives.
Primary Central Nervous System Lymphoma
Primary CNS lymphoma remains one of the most challenging lymphoma subtypes to treat.
Yescarta is currently the only CAR-T product for which the U.S. FDA has removed the previous precaution against use in primary CNS lymphoma. Clinical evidence indicates that the therapy can effectively penetrate the blood-brain barrier and produce meaningful responses in patients with CNS involvement.
Chinese Real-World Data Confirms Clinical Trial Findings
The strong efficacy observed in global clinical trials has also been replicated in routine clinical practice in China.
A real-world study involving 201 Chinese patients with relapsed or refractory large B-cell lymphoma reported:
- Best overall response rate (ORR): 83%
- Complete response rate (CR): 67%
These results closely mirror findings from pivotal international studies.
In addition, Chinese treatment centers reported lower rates of severe cytokine release syndrome (CRS) and severe neurotoxicity compared with some earlier international experiences. Years of clinical experience and standardized management protocols have contributed to improved safety and treatment outcomes.
The Only Approved Second-Line CAR-T Therapy for LBCL in China
One of Yescarta’s most significant advantages in China is its unique regulatory position.
It is currently the first and only CAR-T therapy approved in China for second-line treatment of large B-cell lymphoma.
This approval allows eligible patients to access CAR-T therapy earlier in their disease course rather than waiting until multiple treatment failures occur. Earlier treatment often means patients are in better physical condition and have a greater chance of achieving durable remission and long-term survival.
Looking Ahead
The growing body of evidence supporting Yescarta continues to reshape the treatment landscape for large B-cell lymphoma. With durable five-year survival data, proven second-line benefits, and consistent real-world outcomes in China, CAR-T therapy is increasingly viewed not merely as a salvage treatment but as a potentially curative option for selected patients.
As China’s cellular therapy ecosystem continues to expand, Yescarta stands as a landmark example of how advanced immunotherapy can transform outcomes and offer new hope to patients facing difficult-to-treat lymphoma.
